|
|
|
| * These
news are selected from 'TCT Daily (2004)' provided
by Cardiovascular Research Foundation (CRF). |
The CABERNET trial is a prospective,
single-arm registry evaluating the NexStent (EndoTex)
carotid artery stent and the FilterWire (Boston
Scientific) in patients with carotid artery stenosis
who are also considered at high risk for endarterectomy.
Hopkins is the principal investigator for the CABERNET
study and reported the 30-day results in 443 patients.
The majority of patients (99.1%) in the CABERNET
trial underwent successful FilterWire placement,
while 96.9% of patients underwent successful implantation
of a NexStent carotid stent.
The composite endpoint score of all death, all stroke
and all MI (3.8%) in the CABERNET study is comparable
to the 5.4% rate reported in the BEACH study and
the 7.8% rate reported in both the SAPPHIRE and
ARCHER 2 studies.
CABERNET included symptomatic patients with stenosis
>50% as well as asymptomatic patients with stenosis
>80% measured via ultrasound or at least 60%
measured by angiogram. Patients were also grouped
according to whether they were symptomatic (24.4%)
or asymptomatic (75.6%). |
|
|
|
|
|
